UniSuper Management Pty Ltd Grows Stake in Edwards Lifesciences Corporation $EW

UniSuper Management Pty Ltd lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 29.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 64,031 shares of the medical research company’s stock after acquiring an additional 14,695 shares during the period. UniSuper Management Pty Ltd’s holdings in Edwards Lifesciences were worth $4,980,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $266,000. Park Avenue Securities LLC purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $315,000. Fifth Third Bancorp raised its stake in Edwards Lifesciences by 8.5% during the 2nd quarter. Fifth Third Bancorp now owns 23,870 shares of the medical research company’s stock worth $1,867,000 after acquiring an additional 1,865 shares in the last quarter. Ballentine Partners LLC lifted its position in Edwards Lifesciences by 18.8% in the second quarter. Ballentine Partners LLC now owns 6,072 shares of the medical research company’s stock valued at $475,000 after acquiring an additional 963 shares during the last quarter. Finally, TD Private Client Wealth LLC purchased a new stake in Edwards Lifesciences in the second quarter valued at $169,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.9%

Shares of EW stock opened at $83.70 on Monday. The company has a market capitalization of $48.57 billion, a P/E ratio of 36.08, a price-to-earnings-growth ratio of 3.19 and a beta of 0.95. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $84.99 and its two-hundred day moving average is $80.85. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the business earned $0.67 earnings per share. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the sale, the vice president owned 31,870 shares in the company, valued at $2,729,984.20. This trade represents a 26.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 57,824 shares of company stock worth $4,863,323. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on EW shares. Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Sanford C. Bernstein restated a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Canaccord Genuity Group set a $87.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Citigroup restated a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $96.82.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.